SyntheX

SyntheX expands the druggable proteome using synthetic biology-driven drug discovery platforms. The platforms rely on empirical intracellular selection to discover protein interaction modulators. These can discover compounds that disrupt a specific protein-protein interaction (PPI), or achieve the inverse, and bring an E3 ubiquitin ligase and a neosubstrate of interest together to achieve functional protein degradation. In addition to external discovery collaborations, the platforms have generated an internal oncology pipeline focused on unique mechanisms of action around genetically validated targets.

SyntheX headquartered in United States, North America, operates in the Biotechnology, Life Science, Pharmaceutical, Therapeutics sector. The company focuses on Biotechnology and has secured $1.1B in funding across 96 round(s). With a team of 11-50 employees, SyntheX is actively contributing to advancements in Biotechnology. Their latest funding round, Convertible Note - SyntheX, raised $250.0K. Discover more about their projects, partnerships, and impact on our platform.